A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced.
Durect has signed an agreement with Sandoz to develop and market Posimir (Saber-bupivacaine), an investigational localized pain reliever, in the United States. Durect…
The U.S. Food and Drug Administration (FDA) has granted investigational new drug (IND) status to GKT831, allowing French pharmaceutical company Genkyotex to advance its drug to a Phase…
Novartis is exercising an option to become the exclusive developer and global marketer of Conatus Pharmaceuticals‘ liver-disease treatment emricasan. Under the agreement, signed…
GENFIT has enrolled the first patient in a Phase 2a clinical trial of elafibranor as a treatment for a liver bile duct disease known as primary…
A new online community, called Liver Line and sponsored by Galectin Therapeutics, offers the latest information on liver health and research into liver diseases. On Liver…
Can-Fite BioPharma has concluded preparations for its Phase 2 trial evaluating namodenoson (CF102) for the treatment of non-alcoholic fatty liver disease (NAFLD). The study will…
Researchers at the National University of Singapore have developed a probe that provides doctors with clearer and more accurate magnetic resonance images of liver cancer.
Patients with advanced, inoperable hepatocellular carcinoma (HCC) may highly benefit from Immunitor‘s new oral immunotherapeutic vaccine, Hepko-V5 (hepcortespenlisimut-L), according to results of a Phase 2 trial.
A large observational study is looking at how doctors manage people with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFL). TARGET PharmaSolutions is conducting the…